Literature DB >> 16237393

Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.

Dagmar A Schmid1, Adam Wichniak, Manfred Uhr, Marcus Ising, Hans Brunner, Katja Held, Jutta C Weikel, Annette Sonntag, Axel Steiger.   

Abstract

The noradrenergic and specific serotoninergic antidepressant mirtazapine improves sleep, modulates hormone secretion including blunting of hypothalamic-pituitary-adrenocortical (HPA) activity, and may prompt increased appetite and weight gain. The simultaneous investigation of sleep electroencephalogram (EEG) and hormone secretion during antidepressive treatment helps to further elucidate these effects. We examined sleep EEG (for later conventional and quantitative analyses) and the nocturnal concentrations of cortisol, adrenocorticotropin (ACTH), growth hormone (GH), prolactin, melatonin and the key factors of energy balance, ghrelin, and leptin before and after 28 days of treatment of depressed patients (seven women, three men, mean age 39.9+/-4.2 years) with mirtazapine. In addition, a sleep EEG was recorded at day 2 and the dexamethasone-corticotropin-releasing hormone (DEX-CRH) test was performed to assess HPA activity at days -3 and 26. Psychometry and mirtazapine plasma concentrations were measured weekly. Already at day 2, sleep continuity was improved. This effect persisted at day 28, when slow-wave sleep, low-delta, theta and alpha activity, leptin and (0300-0700) melatonin increased, and cortisol and ghrelin decreased. ACTH and prolactin remained unchanged. The first two specimens of GH collected after the start of quantitative EEG analysis were reduced at day 28. The DEX-CRH test showed, at day 26, a blunting of the overshoot of ACTH and cortisol found at day -3. The Hamilton Depression score decreased from 32.1+/-7.3 to 15.5+/-6.7 between days -1 and 28. A weight gain of approximately 3 kg was observed. This unique profile of changes is compatible with the action of mirtazapine at 5-HT-2 receptors, at presynaptic adrenergic alpha 2 receptors, at the HPA system, and on ghrelin and leptin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16237393     DOI: 10.1038/sj.npp.1300923

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  38 in total

1.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

Review 2.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  Mood disorders: A potential link between ghrelin and leptin on human body?

Authors:  Stalo Zarouna; Greta Wozniak; Anastasia Ioannis Papachristou
Journal:  World J Exp Med       Date:  2015-05-20

4.  Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.

Authors:  Margaret Haney; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Stephanie Collins Reed; Ziva D Cooper; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2010-06-03       Impact factor: 4.530

5.  Biological Consequences of Disturbed Sleep: Important Mediators of Health?

Authors:  Michele L Okun
Journal:  Jpn Psychol Res       Date:  2011-05-01

6.  Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.

Authors:  Sonia Ancoli-Israel; Kimberly E Vanover; David M Weiner; Robert E Davis; Daniel P van Kammen
Journal:  Sleep Med       Date:  2011-01-21       Impact factor: 3.492

7.  Hypersomnia in Mood Disorders: a Rapidly Changing Landscape.

Authors:  David T Plante
Journal:  Curr Sleep Med Rep       Date:  2015-06

8.  Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization.

Authors:  Anne Dekeyne; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

Review 9.  Insomnia in patients with depression: some pathophysiological and treatment considerations.

Authors:  Ripu D Jindal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Assessment of sleep in ventilator-supported critically III patients.

Authors:  Cristina Ambrogio; Jeffrey Koebnick; Stuart F Quan; Marco Ranieri; Sairam Parthasarathy
Journal:  Sleep       Date:  2008-11       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.